VR Logo

Aurobindo Pharma: Completion Of US FDA Inspection At Our Unit VII


Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 and further to our above referred letters this is to inform you that:The Companys Unit VII an oral manufacturing facility situated at Jedcherla Hyderabad received an Establishment Inspection Report (EIR) mentioning the inspection a Voluntary Action Initiated (VAl) from the US FDA and with this inspection is concluded.

Click here to view PDF